Loading stock data…
Zai Lab Limited (ZLAB)
$18.41+0.41 (+2.28%)
After Hours$18.49+0.08 (+0.43%)· Last close Jun 29
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Zai Lab Limited in the Healthcare sector is trading at $18.41 with a market capitalization of $1.9B. Wall Street consensus targets $33.30 (12 analysts), implying a +80.9% move over the next 12 months. The stock is currently near its 52-week low of $15.96, remaining 14.2% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 72 is overbought against a weak tape. The Whystock Score of 20/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +80.9% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Overbought RSI 72 against a weak tape — risk of pullback
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $99.61M↓ | $127.60M↑ | $116.09M↑ | $109.98M↑ | $106.49M |
| Gross Profit | $61.28M↓ | $65.27M↓ | $69.21M↑ | $66.76M↓ | $67.84M |
| Operating Income | -$69.28M↓ | -$68.26M↓ | -$47.97M↑ | -$51.05M↑ | -$56.30M |
| Net Income | -$51.02M↓ | -$50.41M↓ | -$35.96M↑ | -$40.73M↑ | -$48.44M |
Peer Comparison
JNJUNHPFE
Fundamentals
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products includ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.93B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.84
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-26.91%
Volume
Today's trading volume
934,591
Recent News
NovoCure vs. Omeros: Which Emerging Pharmaceutical Stock Is a Better Buy in 2026?
Both companies target serious health challenges, but their financials and risk profiles reveal sharply different paths for growth-focused investors.
Asian Equities Traded in the US as American Depositary Receipts Lower in Wednesday Trading
Asian equities traded in the US as American depositary receipts were lower Wednesday morning, declin
Zai Lab (ZLAB) Is Down 6.0% After Leadership Shake-Up And 2026 Data Focus Has The Bull Case Changed?
On May 21, 2026, Zai Lab Limited announced senior leadership changes, including the departure of President and COO Josh Smiley effective May 22, as part of efforts to enhance operational performance and efficiency while preparing for upcoming product launches and regulatory milestones. The company also emphasized that it expects multiple clinical data readouts in 2026 for its lead global investigational therapies, underscoring a period of operational transition alongside potentially...
Zai Lab (ZLAB) Announces Senior Leadership Changes
Zai Lab Limited (NASDAQ:ZLAB) is one of the 10 Stocks That Have the Potential to Rise 1000%. On May 21, 2026, Zai Lab Limited (NASDAQ:ZLAB) announced senior leadership changes aimed at improving operational performance and efficiency. As part of the changes, the Board decided that Josh Smiley, President and COO, will no longer be with […]
Asian Equities Traded in the US as American Depositary Receipts Decline in Friday Trading; Up for Week
Asian equities traded in the US as American depositary receipts were heading lower Friday morning, d